Vinehealth has received a Class 1 Medical Device CE mark for its Vinehealth mobile app for cancer patients and VinehealthPRO web application for clinicians.

Vinehealth conforms to the requirements of the Medical Devices Directive 93/42/EEC. The Directive outlines safety and performance requirements for medical devices in the UK & EU.

Vinehealth is delighted to announce their partnership with the University of Surrey in securing a £1 million Innovate UK grant to undertake a randomised controlled trial of our cancer companion app.

Newly released ORCHA report "Digital Health for Cancer Services' lists Vinehealth as top in 'best practice’.

Vinehealth is proud to be recognised as one of the top 32 healthtech companies in the UK by Business Leader.

Vinehealth is thrilled to be listed as one of the top 15 health and fitness entrepreneurs to watch in 2021 by the Great British Entrepreneur Awards.

Today, the NHS Innovation Accelerator (NIA) announces the 12 innovators (‘Fellows’) and innovations selected to join its award-winning programme in 2021. These innovations offer solutions to some of the NHS’ most pressing needs and will be supported over the next three years to scale across England for the benefit of NHS patients and staff.

Vinehealth is delighted to announce their collaboration with the National Hospital for Neurology and Neurosurgery (NHNN). Together we will empower brain cancer patients to actively engage in their care using the Vinehealth app and current care pathways at NHNN to improve the patient experiences and provide remote, personalised support.

Healthtech startups have seen a boom in new users, with the sector receiving ‘a $750m investment increase from 2019 to 2020, making it a record year.’ 2020 was also a breakout year for mental health startups, with a sharp increase in both deal numbers and investment figures.

Vinehealth’s co-founder and CEO, Rayna, speaks on Sky News about the work of Vinehealth including the recent £1m Innovate UK grant

We have secured a £1m Innovate UK grant to deliver our cancer companion app to four NHS trusts within a randomised controlled trial. Click through to learn more.